RiverGlades Family Offices LLC bought a new stake in Allergan plc (NYSE:AGN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,245 shares of the company’s stock, valued at approximately $367,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Peloton Wealth Strategists raised its stake in shares of Allergan by 37.1% in the third quarter. Peloton Wealth Strategists now owns 10,485 shares of the company’s stock valued at $2,149,000 after acquiring an additional 2,835 shares during the period. Coronation Fund Managers Ltd. raised its stake in shares of Allergan by 35.9% in the fourth quarter. Coronation Fund Managers Ltd. now owns 203,238 shares of the company’s stock valued at $33,246,000 after acquiring an additional 53,653 shares during the period. Bronfman E.L. Rothschild L.P. raised its stake in shares of Allergan by 16.1% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 5,177 shares of the company’s stock valued at $1,061,000 after acquiring an additional 718 shares during the period. Prudential Financial Inc. raised its stake in shares of Allergan by 1.1% in the third quarter. Prudential Financial Inc. now owns 1,366,552 shares of the company’s stock valued at $280,075,000 after acquiring an additional 14,440 shares during the period. Finally, CNA Financial Corp purchased a new stake in shares of Allergan in the third quarter valued at $2,597,000. 79.66% of the stock is currently owned by institutional investors and hedge funds.
Allergan plc (NYSE:AGN) opened at $162.09 on Friday. The company has a current ratio of 1.16, a quick ratio of 1.88 and a debt-to-equity ratio of 0.38. Allergan plc has a 1-year low of $156.00 and a 1-year high of $256.80. The stock has a market cap of $53,540.00, a PE ratio of -13.52, a price-to-earnings-growth ratio of 1.15 and a beta of 1.19.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The company had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.28 billion. During the same period in the prior year, the business earned $3.90 EPS. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. equities analysts anticipate that Allergan plc will post 15.58 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.78%. This is a boost from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend is Tuesday, February 27th. Allergan’s dividend payout ratio is presently -23.35%.
In other Allergan news, Director Christopher J. Coughlin bought 10,000 shares of the company’s stock in a transaction on Tuesday, December 5th. The shares were bought at an average cost of $163.30 per share, for a total transaction of $1,633,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider William Meury sold 58,879 shares of the stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The disclosure for this sale can be found here. Over the last quarter, insiders have acquired 19,630 shares of company stock worth $3,211,937. 0.36% of the stock is owned by company insiders.
AGN has been the topic of several recent analyst reports. Argus downgraded shares of Allergan from a “buy” rating to a “hold” rating and reduced their target price for the company from $256.80 to $160.07 in a research note on Thursday, December 7th. Deutsche Bank reissued a “buy” rating and issued a $215.00 target price on shares of Allergan in a research note on Tuesday, January 9th. Barclays raised shares of Allergan from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $220.00 to $230.00 in a research note on Monday, January 29th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Allergan from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, Vetr downgraded shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 target price on the stock. in a research note on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company. Allergan has a consensus rating of “Buy” and a consensus target price of $225.94.
COPYRIGHT VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/25/riverglades-family-offices-llc-takes-367000-position-in-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.